$CATX News

Perspective Doses First Brain Tumor Patient in Radiopharmaceutical Study, Expands Cancer Drug Trial to Meningioma Patients

Perspective Therapeutics Reports Early Response SignalS And Favorable Safety Across Three Radiopharmaceutical Programs At ASCO 2026, Including 29% Response Rate In Advanced Melanoma Cohort

Perspective Therapeutics Announces That The First Patients Were Dosed In Two New Cohorts Of Phase 1/2a Studies In Neuroendocrine Tumors And Solid Tumors, Respectively

Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Perspective Therapeutics (NYSEARCA:CATX) Posts Mixed Q1 2026 Results, EPS Beat and Revenue Miss

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estimate

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst Call - Slideshow

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics shares are trading higher after the company announced updated interim results from its ongoing Phase 1/2a clinical trial of VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors as part of a poster presentation at the American Association for Cancer Research Annual Meeting 2026.

Perspective Therapeutics shares are trading higher after the company announced updated interim results from its ongoing Phase 1/2a clinical trial of VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors as part of a poster presentation at the American Association for Cancer Research Annual Meeting 2026.

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Perspective Therapeutics Reports 72% Of Patients Alive Without Disease Progression In Early Cancer Trial, Says 43% Of Patients Show Tumor Response With New Radiotherapy Treatment

HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

UBS Maintains Buy on Perspective Therapeutics, Raises Price Target to $8

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Data At AACR 2026